Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Product, Diabetes Type & End-User According to Strategic Market Research, the market for blood glucose monitoring devices will grow at a robust CAGR of 7.9 percent, from $15.62 billion in 2022, will appreciate and reach $28.75 billion by 2030. With 38.7% of global sales, the North American region will continue to dominate the blood glucose monitoring device market. The blood glucose monitoring devices market is a healthcare industry segment focusing on devices used to measure and monitor blood glucose levels in individuals with diabetes. These devices are crucial in managing diabetes and helping patients maintain optimal blood sugar levels. Blood glucose monitoring devices include continuous glucose monitoring systems, glucose meters, lancets, test strips, and insulin pumps. The growing diabetic population is a significant driver of the blood glucose monitoring devices market. According to International Diabetes Federation, 537 million adults have diabetes. Technological advancements have transformed the blood glucose monitoring devices market by making them more accurate, more user-friendly, and better connected with healthcare providers. CGM systems, for example, provide real-time glucose readings and trends, reducing the need for frequent fingerstick tests. Integrating mobile apps and wireless connectivity has enhanced data management and improved patient outcomes. Dominating market leaders like Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Dexcom, Inc., and Ascensia Diabetes Care Holdings AG are investing in research and development to introduce innovative products. The blood glucose monitoring devices market is subject to stringent regulations to ensure patient safety and device efficacy. The FDA and EMA look after device approval and post-market surveillance. Impact of Covid-19 You will find a wide range of blood glucose monitors in the market with different features and sizes, prices, and testing times. Several countries went on lockdown during the Coronavirus outbreak to control the spread. The lockdown has resulted in changes in the daily routines of diabetic patients, including the way they eat, exercise, and remain sedentary. The abnormal fluctuations in blood glucose levels caused by these have increased the demand for glucose monitoring devices. In recent months, online sales of all self-monitoring devices have shot up dramatically. Moreover, the lockdown led to the stockpiling of blood glucose monitors. Report Coverage & Deliverables:- The PDF report provides the following information: Opportunity in the regional market Benchmarking competitiveness Statistics and forecasts for the past and future Revenue shares of the companies Trends and dynamics of the market Market Drivers: Rising Prevalence in Diabetic Patients & Advancements in Glucose Sensing Devices. Chronic diabetes impacts the body's capacity to control blood sugar levels. Blood glucose levels must be regularly monitored if diabetes is to be effectively managed and complications are to be avoided. This need for continuous monitoring has created a significant demand for blood glucose monitoring devices in the market. As per WHO, there are 422 Mn diabetic patients worldwide which directly causes 1.5 million deaths yearly. This rising prevalence of diabetic patients drives the blood glucose monitoring devices market for continuous monitoring of blood glucose levels and adjusting medication dosage. Diabetes is a chronic disease affecting 8.5% of the world's population and induces an annual expenditure of $1.3 trillion. The pre-Diabetic condition indicates early diagnostics and monitoring for effective blood sugar management, raising the demand for advanced blood glucose level monitoring devices. Senseonics' Eversense is the first FDA-approved system with a fully implantable sensor that can measure glucose levels for up to 90 days, and it also has an intelligent transmitter to send data to a mobile app to convert real-time data into charts and graphs. The Combo Glucometer (CoG) is the first and only commercially available non-invasive product for glucose monitoring. It uses a digital image sensor to assess reflected light from tissue and employs proprietary algorithms to measure blood glucose levels. Abbott has launched the FreeStyle Libre flash glucose monitoring system, an easy-to-use, portable point-of-care system. The patient uses a handheld scanner to monitor the reading. The product is available in Europe and the United States and is 25% less in terms of cost than a standalone CGM in a favorable reimbursement environment. The introduction and high adaptability of the above devices is going to propel the market for Blood Glucose monitoring at a substantially high rate. Market Analysis Of Different Segments Covered in the Report Product Outlook Continuous Blood Glucose Monitoring Devices Sensors Transmitter & Receiver Insulin Pumps Self-monitoring Devices Blood Glucose Meter Testing Strips Lancets Based on Applications Type 1 diabetes Type 2 diabetes Based on End-User Home Care Hospitals Diagnostics Centres Regional Coverage Analysis North America US Canada Mexico Rest of North America Europe France U.K Netherlands Switzerland Germany Finland Belgium Russia Italy Spain Turkey Rest of Europe Asia Pacific China Japan India South Korea Malaysia Australia Singapore Thailand Indonesia Philippines Rest of Asia-Pacific LAMEA Brazil Argentina Uruguay Saudi Arabia Rest of LAMEA Based on Product Type: Self-Monitoring Blood Glucose Devices (SMBG) will dominate the market over the forecast period:- The blood glucose monitoring devices are broadly categorized as Continuous blood glucose monitoring devices & self-monitoring devices. Self-monitoring blood glucose devices are leading the segment with 68.3% of the market share and is expected to dominate the industry during the forecasted period. Diabetes is becoming more prevalent worldwide as 536 million adults are expected to have the disease by 2023. Regular blood glucose monitoring is crucial for individuals with diabetes to manage their medications effectively. SMBG devices allow individuals to measure their blood glucose levels at home, providing immediate feedback on their current status. SMBG devices have undergone significant technological advancements, making them more user-friendly, accurate, and convenient. Modern devices are often compact, portable, and require only a tiny blood sample. SMBG provides quick results and may feature features like memory storage, trend analysis, and connectivity to smartphones or other devices for data tracking and sharing with healthcare professionals. Regular monitoring of the patients’ blood glucose levels, makes them better understand how their bodies respond to different factors like diet, exercise, stress, and medication. Continuous blood glucose monitoring devices will witness the fastest growing CAGR in the market, primarily due to real-time glucose level monitoring with the help of a wearable continuous glucose monitor. A CGM consists of Sensors, Transmitter and Receiver, and Insulin Pumps. CGM tracks blood glucose levels at all the times, and the software analyses the trends in the glucose level and shares data with the healthcare provider to remotely gain insight into how factors from daily life affect the glucose level. In 2019, Private Label blood-glucose meters sold 13.1 million units and generated 167.1 million US dollars. 2nd in position is Lifescan One Touch Ultra, with almost 32.2 million US dollars in sales. Roche announced in January 2022 the Cobas Pulse system, which is an industry first, combining the form factor of a good and high-class performance blood glucose meter along with simple usability & expanded digital potential akin to a smartphone. The Cobas pulse system provides a digital health application based on the Android operating system that performs a range of clinically valuable functions ranging from digital clinical support to the measurement of vital signs & digital biomarkers. At the time of the launch, Roche has already secured partnerships with startups in the field, namely Glytec, CardioSignal, Steady Sense, and SD4X. Over 33 million people in Europe have diabetes, out of which around seven million people are from Germany, and this figure is forecasted to shoot up. Around 2 million people with diabetes wore the monitors in 2020, twice the number from 2019. CGM is a wearable technology that automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. It is a tool for people with diabetes. Insulin is a hormone that assists your body in regulating blood sugar levels. Diabetes patients must give themselves insulin regularly to maintain their blood sugar levels. Tracking blood sugar informs about the body's insulin and in what quantity. Abbott Laboratories, one of the giants in CGM devices, has achieved tremendous success with FreeStyle Libre technology. It is in the no.1 spot in the CGM market with a 3.5 million increase in customers, all in just six years. Abbott laboratories produce 10 million sensors available around the globe in sixty countries. Machine learning will come into consideration and will play a vital role as people with diabetes are forecasted to grow by 51%, and by 2045, 700 million people will have diabetes that will need dense glucose data, and this can be possible with Freestyle libre technology. Right now, around 3.5 million people are using this technology. Dexcom’s CGM in the field of diabetes worldwide revenue grew by 17% to $ 696.2 million in the 2nd quarter of 2022, up from $595.1 million in the 2nd quarter of 2021. In 2021, it made $2.45 billion in revenue, up 27% from its $1.9 billion in 2020. Patient volumes in and outside the US are in the 30%-40% range. Dexcom's top achievement of 2021 was the publication of data demonstrating the effectiveness of its latest model G7 CGM sensor. The G7 device is 60% smaller than the G6, designed for patients with type-1 or types-2 diabetes to trace their glucose levels. Based on Application: Type 2 diabetes will dominate the market over the forecast period:- Most diabetes cases are usually caused by type 2 diabetes, accounting for 89.2% of all cases. A large amount of insulin does not get appropriately used when you have type 2 diabetes. To effectively treat type 2 diabetes, lifestyle factors such as physical activity and nutrition need to be considered. Patients with type 2 diabetes will eventually require oral medications and insulin to maintain proper blood glucose levels. Type 1 diabetes cases can occur in any issue, but it occurs mainly in children and adolescents. Unfortunately, research cannot pinpoint the cause of the disease because the body's immune system mistakenly kills the Insulin-producing (islets, or islets of Langerhans) cells in the pancreas, which usually fights harmful bacteria and viruses. Based on End-User: Hospitals will dominate the market over the forecast period:- The Blood Glucose Monitoring Device market is categorized into Home Care, Hospitals, and Diagnostics Centres. The hospital segment dominates the sector with a 43.62% market share and is estimated to dominate the industry during the forecasted period. The number of diabetic patients is higher in hospitals, particularly those with more complicated cases which has increased the demand for blood glucose monitoring devices. Real-time blood glucose monitoring of hospitalized patients is done by CGM systems and point-of-care (POC) glucose meters. These devices provide healthcare professionals with accurate and timely data, allowing them to adjust medication dosages and develop appropriate treatment plans. With Technological advancements, continuous glucose monitoring (CGM) systems have evolved to provide real-time glucose measurements, trend data, alarms, and data-sharing capabilities. Blood glucose monitoring devices are now easier to use, enabling healthcare professionals to make data-driven decisions for better patient care. The Home Care segment is the fastest growing market for blood glucose monitoring devices because it enables individuals to monitor their blood glucose levels regularly without requiring frequent hospital visits. These devices are user-friendly, portable, and provide quick results, making them suitable for self-monitoring of blood glucose by patients. Based on Regional Assessment, the APAC region is driving the market growth at the highest CAGR rate:- Considering the increasing incidence of obesity, unhealthy diet, and physical inactivity, North America commanded the most extensive blood glucose monitoring device market with a market share of 38.7% of the market. According to the Centers for Disease Control and Prevention (CDC), the number of people aged 18 and older with diabetes, as well as those who were undiagnosed, was 30.3 million in 2015. This data represents 9.4% of the entire US population. According to the CDC data, there are 23.1 million diagnosed diabetics in the United States, i.e., 7.2% of the total population. The existence of highly developed technologies, high healthcare expenditure, increased research and development activities, and large concentrations of significant companies have all contributed to the growth of this market. A study by the International Diabetes Federation projects that the total expenditure on diabetes in Europe for the age group between 20 to 79 will rise to $178 bn by 2040. To tackle diabetes, wearable technology such as continuous glucose monitoring (CGM) systems alert parents, patients, or care takers during actual or upcoming glycaemic encounters. The market for CGM wearables devices is expected to increase as they are becoming increasingly affordable with the introduction of new technology. The well-established healthcare infrastructure, favourable reimbursement policies, and a growing aging population drives the market growth in Europe. The Asia Pacific region offers significant growth opportunities for the blood glucose monitoring devices market. Rapid urbanization, changing lifestyles, and the increasing prevalence of diabetes in countries like China and India are significant drivers for market growth in the APAC region. Additionally, the rising awareness about diabetes management and adoption of advanced technologies contribute to market expansion. Insights on the top companies and their market share:- The top players expand their business portfolios by launching new products, making acquisitions, improving their existing products and technologies, and engaging in other activities to strengthen their presence. For instance, Roche launched the Accu-Chek Guide blood glucose monitoring device in August 2016. The company designed the device to reach glucose goals with ease; the device offers glucose monitoring throughout the day. Blood Glucose Monitoring Devices Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 14.48 Billion The revenue forecast in 2030 USD 28.75 Billion Growth rate CAGR of approximately 7.9% The base year for estimation 2021 Historical data 2017 – 2021 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Type, By Application, By Region By Type Self-Monitoring Blood Glucose Devices (SMBG)(Blood glucose meters, testing strips, Lancets), Continuous Blood Glucose Monitoring Devices(Sensors, Transmitter and receiver, Insulin pumps). By Application Type 2 diabetes,Type 1 diabetes By Region North America, Europe, Asia Pacific, Australian Bureau of Statistics. Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Medtronic, B. Braun Melsungen, Nipro, Sanofi, Arkray, Abbott Laboratories, F. Hoffmann-La Roche, Ypsomed, Prodigy Diabetes Care, Acon Laboratories, Nova BiomedicalLifescan, Ascensia Diabetes Care, Dexcom. Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Blood Glucose Monitoring Devices Market Competitive Landscape Analysis Medtronic B. Braun Melsungen Nipro Sanofi Arkray Abbott Laboratories F. Hoffmann-La Roche Ypsomed Prodigy Diabetes Care Acon Laboratories Nova BiomedicalLifescan Ascensia Diabetes Care Dexcom Recent Development: - On February 2023, According to Bloomberg, Apple is progressing towards developing a non-invasive blood glucose monitoring device that could be incorporated into the Apple Watch. The non-invasive device will use lasers to detect glucose levels, replacing the traditional finger prick test. It is currently in the early stage and could be made commercially available once it is made smaller. On November 2022, The GlucoRx BioXensor became the world's first multiple-sensor & non-invasive type of continuous glucose monitor (CGM). It measures blood glucose levels once every minute, reliably, accurately, and non-invasively using patented radio frequency technology and a multiple sensor approach. Applications can be an early intervention to change lifestyle and improve quality of life with its smart alarms and remote monitoring technology. Due to its non-chemical action, they have developed a wearable device with a longer shelf-life. Frequently Asked Question About This Report Which is a recently approved blood glucose monitoring device? On 21st June 2021, For people 18 years of age and older with diabetes, the US FDA has approved the Eversense Continuous Glucose Monitoring (CGM) system. This device is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, worn for up to 90 days. What was the share of type 2 diabetes patients in the blood glucose monitoring devices market? Patients with type 2 diabetes comprise 89.2% of the blood glucose monitoring device market. How big will the Blood Glucose Monitoring Devices Market be? The global blood glucose monitoring devices market size was $14.48 billion in 2021 and is predicted to reach $28.75 billion by 2030, at a CAGR of 7.9% during the forecast period of 2021 - 2030. What is the projected growth rate of the market? The projected growth rate of blood glucose monitoring devices is 7.91% throughout the forecasted period. Which region is estimated to grow at the fastest rate in the market? The APAC region, due to its market potential, has the highest growth rate in the market. Which region has the largest share in the market? North America accounted for the largest share in the market. What is the present total market value of the market report? The Global blood glucose monitoring devices current market size is $14.48 billion in 2021. Which companies dominate the market? In the market for blood glucose monitoring systems, the significant players are Roche (Switzerland), Abbott (US), LifeScan (US), Medtronic (Ireland), Dexcom (US), Ypsomed (Switzerland), B. Braun (Germany), Ascensia (Switzerland), Nipro (Japan), Sanofi (France), ARKRAY (Japan), Prodigy Diabetes Care (US), ACON Laboratories (US), and Nova Biomedical (US). Sources https://www.who.int/news-room/facts-in-pictures/detail/6-facts-on-obesity https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html https://www.ncbi.nlm.nih.gov/books/NBK513253/ https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf https://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf https://en.wikipedia.org/wiki/Blood_glucose_monitoring https://www.diabetesincontrol.com/new-researches-in-diabetes/ https://www.diabetesatlas.org/en/ https://www.who.int/health-topics/diabetes#tab=tab_1 Chapter 1. Introduction 1.1 Study Objectives 1.2 Market Definition Table 1 Inclusion and Exclusions 1.3 Study Scope 1.3.1 Markets Covered Figure 01: Market Segmentation 1.3.2 Geographic Scope Figure 02: Market Geography covered 1.3.3 Years Considered 1.4 Stakeholders Chapter 2. Research Methodology 2.1 Data Procurement 2.2 Paid Database 2.2.1 Secondary Data 2.2.1.1 Key Secondary sources 2.2.2 Primary Data 2.2.2.1 Primary sources 2.2.2.2 Key industry insights 2.2.2.3 Primary interviews with experts 2.2.2.4 Key primary respondent list 2.3 Market Size Estimation 2.4 Bottom-Up and Top-Down Approaches 2.4.1 Bottom-Up Approach 2.4.1.1 Approach for arriving at market size by bottom-up analysis Figure 03: Market: Bottom-Up Approach 2.4.2 Top-Down Approach 2.4.2.1 Approach for Capturing Market Size by Top-Down Analysis Figure 04: Market: Top-Down Approach 2.5 Market Breakdown and Data Triangulation Figure 05: Data Triangulation 2.6 Research Methodology 2.7 Risk Assessment Table 2: Risk Assessment Chapter 3. Executive Summary 3.1 Market: Post-Covid-19 Figure 06: Impact of Covid-19 on Market 3.1.1 Actual Scenario Figure 07: Realistic Scenario: Market, 2020–2028 (USD Million) 3.1.2 Pessimistic Scenario Figure 08: Pessimistic Scenario: Market, 2020–2028 (USD Million) 3.1.3 Optimistic Scenario Figure 09: Optimistic Scenario: Market, 2020–2028(USD Million) 3.1.4 Market Summary Figure 10: Self-Monitoring Blood Glucose Devices (SMBG) to Witness Highest CAGR in Market, By Product Type, During Forecast Period Figure 11: Hospital segment to Witness Higher CAGR in Market for End-User Segment during Forecast Period Figure 12: type 2 diabetes for Application to Register Highest CAGR in Market during Forecast Period Figure 13: North America to Account for Largest Share of Global Market In 2020 Chapter 4. Market Definitions 4.1 Market Segmentation Figure 14: Market Segmentation Chapter 5. Industry Outlook 5.1 Global Blood Glucose Monitoring Devices Market Snapshot 5.2 Global Market 5.2.1 Global market, 2020 – 2028 (USD Million) 5.3 Regional Segment Analysis 5.3.1 Global market, by region, 2021 - 2030 (USD Million) 5.4 Product Type Segment Analysis 5.4.1 Global market, by Product Type, 2021 - 2030 (USD Million) 5.5 End-User Analysis 5.5.1 Global market, by End-User, 2021 - 2030 (USD Million) 5.6 Application Segment Analysis 5.6.1 Global market, by Application, 2021 - 2030 (USD Million) 5.7 By Usage Business Analysis 5.8 Value Chain Analysis 5.9 Market Variable Analysis 5.9.1 Market Drivers Analysis 5.9.2 Market Restraints Analysis 5.10 Business Environment Analysis Tool 5.10.1 Market PEST analysis 5.10.2 Market Porter’s analysis 5.11 Penetration & Growth Prospect Mapping Chapter 6. Market Overview 6.1 Introduction 6.2 Market Dynamics Figure 15 Market: Drivers, Restraints, Opportunities, and Challenges 6.2.1 Drivers Figure 16 Market Drivers and Their Impact 6.2.2 Restraints Figure 17 Market Restraints and Their Impact 6.2.3 Opportunities Figure 18 Market Opportunities and Their Impact 6.2.4 Challenges Figure 19 Market Challenges and Their Impact 6.3 Impact of Covid-19 on Market 6.4 Value Chain Analysis Figure 20 Value Chain Analysis: Market 6.5 Ecosystem Figure 21 Market: Ecosystem Table 3 Market: Ecosystem Figure 22 Revenue Shift in Market 6.6 Patent Analysis Table 4 Number of Patents Registered in Market in USA in Last 9 Years Figure 23 Top 13 Companies with Highest No. of Patents in Last 9 Years Figure 24 No of Patents Granted Per Year, 2019–2020 Table 5 List of Global Patents in Market 6.7 Trade Analysis Figure 25 Import Data for Self-Monitoring Blood Glucose Devices (SMBG), By Country, 2016–2020 (USD Thousand) Table 6 Import Data for Continuous, By Country, 2016–2020 (USD Thousand) Figure 26 Export Data for Self-Monitoring Blood Glucose Devices (SMBG), By Country, 2016–2020 (USD Thousand) Table 7 Export Data for Continuous, By Country, 2016–2020 (USD Thousand) 6.8 Tariff Analysis 6.9 Case Study Analysis 6.10 Porter’s Five Forces Analysis Table 8 Market: Porter’s Five Forces Analysis, 2020 6.10.1 Threat of New Entrants 6.10.2 Threat of Substitutes 6.10.3 Bargaining Power of Buyers 6.10.4 Bargaining Power of Suppliers 6.10.5 Degree of Competition 6.11 Technology Analysis 6.11.1 Trends in Technology (2014-2020) 6.11.2 Trends in Technology (2021-2028) Table 9 Key Regulations: Market 6.12 Pricing Analysis 6.12.1 Average Price Trend Analysis (By region, By Countries) Chapter 7. Competitive & Vendor Landscape 7.1 Company Market Share Analysis Table 10: Key Players market share Figure 27: Key players market share of companies 7.2 Manufacturers Manufacturing Sites, Area Served, Product Type Product Type 7.3 Market Competitive Situation and Trends 7.4 Manufacturers Mergers & Acquisitions, Expansion Plans Chapter 8. Global Market: Product Type Segment Analysis 8.1 Introduction 8.2 Sales Volume & Revenue Analysis (2020-2028) Table 11 Markets, By Product Type, 2021–2028 (USD Million) Figure 28 Markets, By Product Type Figure 29 Self-Monitoring Blood Glucose Devices (SMBG) Segment to Register Highest CAGR in Market during Forecast Period 8.3 Self-Monitoring Blood Glucose Devices (SMBG) 8.3.1 Self-Monitoring Blood Glucose Devices (SMBG) market, 2021 - 2030 (USD Million) 8.3.1.1 Blood glucose meters market, 2021 - 2030 (USD Million) 8.3.1.2 Testing strips market, 2021 - 2030 (USD Million) 8.3.1.3 Lancets market, 2021 - 2030 (USD Million) Figure 30: Self-Monitoring Blood Glucose Devices (SMBG) market, 2021 - 2030 (USD Million) 8.4 Continuous 8.4.1 Continuous market, 2021 - 2030 (USD Million) 8.4.1.1 Sensors market, 2021 - 2030 (USD Million) 8.4.1.2 Transmitter and receiver market, 2021 - 2030 (USD Million) 8.4.1.3 Insulin pumps market, 2021 - 2030 (USD Million) Figure 31: Continuous market, 2021 - 2030 (USD Million) Chapter 9. Global Market: End-User Segment Analysis 9.1 Introduction 9.2 Sales Volume & Revenue Analysis (2020-2028) Table 12: Market, By End-User, 2021–2028 (USD Million) Figure 32 Markets, By End-User, 2021–2028 (USD Million) Figure 33: Hospitals to Register Highest CAGR in Market during Forecast Period 9.3 Hospitals 9.3.1 Hospitals market, 2021 - 2030 (USD Million) Figure 34: Hospitals market, 2021 - 2030 (USD Million) 9.4 Home Care 9.4.1 Home Care market, 2021 - 2030 (USD Million) Figure 35: Home Care market, 2021 - 2030 (USD Million) 9.5 Diagnostic centers 9.5.1 Diagnostic centers market, 2021 - 2030 (USD Million) Figure 36: Diagnostic centers market, 2021 - 2030 (USD Million) Chapter 10. Global Market: Applications Segment Analysis 10.1 Introduction 10.2 Sales Volume & Revenue Analysis (2020-2028) Table 13: Market, By Application, 2021–2028 (USD Million) Figure 37: Market, By Application, 2021–2028 (USD Million) Figure 38: type 2 diabetes Segment to Register Highest CAGR in Market during Forecast Period 10.3 Type 2 diabetes 10.3.1 Type 2 diabetes market, 2021 - 2030 (USD Million) Figure 39: Type 2 diabetes market, 2021 - 2030 (USD Million) 10.4 Type 1 diabetes 10.4.1 Type 1 diabetes market, 2021 - 2030 (USD Million) Figure 40: Type 1 diabetes market, 2021 - 2030 (USD Million) Chapter 11. Global Market: Regional Outlook 11.1 North America Figure 41: North America Market, By Revenue Forecast (2020-2028) 11.1.1 North America market, by country, 2021 - 2030 (USD Million) Table 14: North America Market, by Country, 2020-2028 Figure 42: North America Market 11.1.2 North America market, by Product Type, 2021 - 2030 (USD Million) Table15: North America market, by Product Type, 2021 - 2030 (USD Million) Figure 43: North America market, by Product Type, 2021 - 2030 (USD Million) 11.1.3 North America market, by End-User, 2021 - 2030 (USD Million) Table 16: North America market, by End-User, 2021 - 2030 (USD Million) Figure 44: North America market, by End-User, 2021 - 2030 (USD Million) 11.1.4 North America market, by Application, 2021 - 2030 (USD Million) Table 17: North America market, by Application, 2021 - 2030 (USD Million) Figure 45: North America market, by Application, 2021 - 2030 (USD Million) 11.1.5 U.S. 11.1.5.1 U.S. Market, by Product Type, 2021 - 2030 (USD Million) Figure 46: U.S. Market, by Product Type, 2021 - 2030 (USD Million) 11.1.5.2 U.S. Market, by End-User, 2021 - 2030 (USD Million) Figure 47: U.S. Market, by End-User, 2021 - 2030 (USD Million) 11.1.5.3 U.S. Market, by Application, 2021 - 2030 (USD Million) Figure 48: U.S. Market, by Application, 2021 - 2030 (USD Million) 11.1.6 Canada 11.1.6.1 Canada market, by Product Type, 2021 - 2030 (USD Million) Figure 49: Canada market, by Product Type, 2021 - 2030 (USD Million) 11.1.6.2 Canada market, by End-User, 2021 - 2030 (USD Million) Figure 50: Canada market, by End-User, 2021 - 2030 (USD Million) 11.1.6.3 Canada market, by Application, 2021 - 2030 (USD Million) Figure 51: Canada market, by End-User, 2021 - 2030 (USD Million) 11.1.6.4 Canada market, by Application, 2021 - 2030 (USD Million) Figure 52: Canada market, by End-User, 2021 - 2030 (USD Million) 11.2 Europe Figure 53: Europe Market, By Revenue Forecast (2020-2028) 11.2.1 Europe market, by country, 2021 - 2030 (USD Million) Table 18: Europe market, by country, 2021 - 2030 (USD Million) Figure 54: Europe market, by country, 2021 - 2030 (USD Million) 11.2.2 Europe market, by Product Type, 2021 - 2030 (USD Million) Table 19: Europe market, by Product Type, 2021 - 2030 (USD Million) Figure 55: Europe market, by Product Type, 2021 - 2030 (USD Million) 11.2.3 Europe market, by End-User, 2021 - 2030 (USD Million) Table 20: Europe market, by End-User, 2021 - 2030 (USD Million) Figure 56: Europe market, by End-User, 2021 - 2030 (USD Million) 11.2.4 Europe market, by Application, 2021 - 2030 (USD Million) Table 21: Europe market, by Application, 2021 - 2030 (USD Million) Figure 57: Europe market, by Application, 2021 - 2030 (USD Million) 11.2.5 U.K. 11.2.5.1 U.K. Market, by Product Type, 2021 - 2030 (USD Million) Figure 58: U.K. Market, by Product Type, 2021 - 2030 (USD Million) 11.2.5.2 U.K. Market, by End-User, 2021 - 2030 (USD Million) Figure 59: U.K. Market, by End-User, 2021 - 2030 (USD Million) 11.2.5.3 U.K. Market, by Application, 2021 - 2030 (USD Million) Figure 60: U.K. Market, by Application, 2021 - 2030 (USD Million) 11.2.6 Germany 11.2.6.1 Germany market, by Product Type, 2021 - 2030 (USD Million) Figure 61: Germany market, by Product Type, 2021 - 2030 (USD Million) 11.2.6.2 Germany market, by End-User, 2021 - 2030 (USD Million) Figure 62: Germany market, by End-User, 2021 - 2030 (USD Million) 11.2.6.3 Germany market, by Application, 2021 - 2030 (USD Million) Figure 63: Germany market, by Application, 2021 - 2030 (USD Million) 11.2.7 France 11.2.7.1 France market, by Product Type, 2021 - 2030 (USD Million) Figure 64: France market, by Product Type, 2021 - 2030 (USD Million) 11.2.7.2 France market, by End-User, 2021 - 2030 (USD Million) Figure 65: France market, by End-User, 2021 - 2030 (USD Million) 11.2.7.3 France market, by Application, 2021 - 2030 (USD Million) Figure 66: France market, by Application, 2021 - 2030 (USD Million 11.2.8 Rest of Europe 11.2.8.1 Rest of Europe market, by Product Type, 2021 - 2030 (USD Million) Figure 67: Rest of Europe market, by Product Type, 2021 - 2030 (USD Million) 11.2.8.2 Rest of Europe market, by End-User, 2021 - 2030 (USD Million) Figure 68: Rest of Europe market, by End-User, 2021 - 2030 (USD Million) 11.2.8.3 Rest of Europe market, by Application, 2021 - 2030 (USD Million) Figure 69: Rest of Europe market, by Application, 2021 - 2030 (USD Million) 11.3 Asia Pacific Figure 70: Asia Pacific Market, By Revenue Forecast (2020-2028) 11.3.1 Asia Pacific market, by country, 2021 - 2030 (USD Million) Table 22: Asia Pacific market, by country, 2021 - 2030 (USD Million) Figure 71: Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.2 Asia Pacific market, by Product Type, 2021 - 2030 (USD Million) Table 23: Asia Pacific market, by Product Type, 2021 - 2030 (USD Million) Figure 72: Asia Pacific market, by Product Type, 2021 - 2030 (USD Million) 11.3.3 Asia Pacific market, by End-User, 2021 - 2030 (USD Million) Table 24: Asia Pacific market, by End-User, 2021 - 2030 (USD Million) Figure 73 Asia Pacific market, by End-User, 2021 - 2030 (USD Million) 11.3.4 Asia Pacific market, by Application, 2021 - 2030 (USD Million) Table 25: Asia Pacific market, by Application, 2021 - 2030 (USD Million) Figure 74: Asia Pacific market, by Application, 2021 - 2030 (USD Million) 11.3.5 China 11.3.5.1 China market, by Product Type, 2021 - 2030 (USD Million) Figure 76: China market, by Product Type, 2021 - 2030 (USD Million) 11.3.5.2 China market, by End-User, 2021 - 2030 (USD Million) Figure 77: China market, by End-User, 2021 - 2030 (USD Million) 11.3.5.3 China market, by Application, 2021 - 2030 (USD Million) Figure 78: China market, by Application, 2021 - 2030 (USD Million) 11.3.6 India 11.3.6.1 India market, by Product Type, 2021 - 2030 (USD Million) Figure 79: India market, by Product Type, 2021 - 2030 (USD Million) 11.3.6.2 India market, by End-User, 2021 - 2030 (USD Million) Figure 80: India market, by End-User, 2021 - 2030 (USD Million) 11.3.6.3 India market, by Application, 2021 - 2030 (USD Million) Figure 81: India market, by Application, 2021 - 2030 (USD Million) 11.3.7 Japan 11.3.7.1 Japan market, by Product Type, 2021 - 2030 (USD Million) Figure 82: Japan market, by Product Type, 2021 - 2030 (USD Million) 11.3.7.2 Japan market, by End-User, 2021 - 2030 (USD Million) Figure 83: Japan market, by End-User, 2021 - 2030 (USD Million) 12.3.7.3 Japan market, by Application, 2021 - 2030 (USD Million) Figure 84: Japan market, by Application, 2021 - 2030 (USD Million) 11.3.8 South Korea 11.3.8.1 South Korea market, by Product Type, 2021 - 2030 (USD Million) Figure 85: South Korea market, by Product Type, 2021 - 2030 (USD Million) 11.3.8.2 South Korea market, by End-User, 2021 - 2030 (USD Million) Figure 86: South Korea market, by End-User, 2021 - 2030 (USD Million) 12.3.8.3 South Korea market, by Application, 2021 - 2030 (USD Million) Figure 87: South Korea market, by Application, 2021 - 2030 (USD Million) 11.3.9 Rest of APAC 11.3.9.1 Rest of APAC market, by Product Type, 2021 - 2030 (USD Million) Figure 88 Rest of APAC market, by Product Type, 2021 - 2030 (USD Million) 11.3.9.2 Rest of APAC market, by End-User, 2021 - 2030 (USD Million) Figure 89: Rest of APAC market, by End-User, 2021 - 2030 (USD Million) 11.3.9.3 Rest of APAC market, by Application, 2021 - 2030 (USD Million) Figure 90: Rest of APAC market, by Application, 2021 - 2030 (USD Million) 11.4 Latin America Figure 91: Latin America Market, By Revenue Forecast (2020-2028) 11.4.1 Latin America market, by country, 2021 - 2030 (USD Million) Table 26: Latin America market, by country, 2021 - 2030 (USD Million) Figure 92: Latin America market, by country, 2021 - 2030 (USD Million) 11.4.2 Latin America market, by Product Type, 2021 - 2030 (USD Million) Table 27: Latin America market, by Product Type, 2021 - 2030 (USD Million) Figure 93: Latin America market, by Product Type, 2021 - 2030 (USD Million) 11.4.3 Latin America market, by End-User, 2021 - 2030 (USD Million) Table 28: Latin America market, by End-User, 2021 - 2030 (USD Million) Figure 94: Latin America market, by End-User, 2021 - 2030 (USD Million) 11.4.4 Latin America market, by Application, 2021 - 2030 (USD Million) Table 29: Latin America market, by Application, 2021 - 2030 (USD Million) Figure 95: Latin America market, by Application, 2021 - 2030 (USD Million) 11.4.5 Brazil 11.4.5.1 Brazil market, by Product Type, 2021 - 2030 (USD Million) Figure 96: Brazil market, by Product Type, 2021 - 2030 (USD Million) 11.4.5.2 Brazil market, by End-User, 2021 - 2030 (USD Million) Figure 97: Brazil market, by End-User, 2021 - 2030 (USD Million) 11.4.5.3 Brazil market, by Application, 2021 - 2030 (USD Million) Figure 98: Brazil market, by Application, 2021 - 2030 (USD Million) 11.4.6 Mexico 11.4.6.1 Mexico market, by Product Type, 2021 - 2030 (USD Million) Figure 99: Mexico market, by Product Type, 2021 - 2030 (USD Million) 11.4.6 2 Mexico market, by End-User, 2021 - 2030 (USD Million) Figure 101: Mexico market, by End-User, 2021 - 2030 (USD Million) 11.4.6.3 Mexico market, by Application, 2021 - 2030 (USD Million) Figure 102: Mexico market, by Application, 2021 - 2030 (USD Million) 11.4.7 Rest of the Latin America 11.4.7.1 Rest of the Latin America market, by Product Type, 2021 - 2030 (USD Million) Figure 103: Rest of the Latin America market, by Product Type, 2021 - 2030 (USD Million) 11.4.7.2 Rest of the Latin America market, by End-User, 2021 - 2030 (USD Million) Figure 104: Rest of the Latin America market, by End-User, 2021 - 2030 (USD Million) 11.4.7.3 Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) Figure 105: Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) 11.5 MEA Figure 106: MEA Market, By Revenue Forecast (2020-2028) 11.5.1 MEA market, by Product Type, 2021 - 2030 (USD Million) Figure 107: MEA market, by Product Type, 2021 - 2030 (USD Million) 11.5.2 MEA market, by End-User, 2021 - 2030 (USD Million) Figure 108: MEA market, by End-User, 2021 - 2030 (USD Million) 11.5.3 MEA market, by Application, 2021 - 2030 (USD Million) Figure 109: MEA market, by Application, 2021 - 2030 (USD Million) Chapter 12. Competitive Landscape 12.1 Medtronic. 12.1.1 Company overview 12.1.2 Financial performance 12.1.3 Product Type Portfolio Analysis 12.1.4 Business Strategy & Recent Development 12.2 B. Braun Melsungen. 12.2 .1 Company overview 12.2 .2 Financial performance 12.2 .3 Product Type Portfolio Analysis 12.2 .4 Business Strategy & Recent Development 12.3 Nipro. 12.3.1 Company overview 12.3.2 Financial performance 12.3.3 Product Type Portfolio Analysis 12.3.4 Business Strategy & Recent Development 12.4 Sanofi. 12.4.1 Company overview 12.4.2 Financial performance 12.4.3 Product Type Portfolio Analysis 12.4.4 Business Strategy & Recent Development 12.5 Arkray. 12.5.1 Company overview 12.5.2 Financial performance 12.5.3 Product Type Portfolio Analysis 12.5.4 Business Strategy & Recent Development 12.6 Abbott Laboratories. 12.6.1 Company overview 12.6.2 Financial performance 12.6.3 Product Type Portfolio Analysis 12.6.4 Business Strategy & Recent Development 12.7 F. Hoffmann-La Roche. 12.7.1 Company overview 12.7.2 Financial performance 12.7.3 Product Type Portfolio Analysis 12.7.4 Business Strategy & Recent Development 12.8 Ypsomed. 12.8.1 Company overview 12.8.2 Financial performance 12.8.3 Product Type Portfolio Analysis 12.8.4 Business Strategy & Recent Development 12.9 Prodigy Diabetes Care. 12.9.1 Company overview 12.9.2 Financial performance 12.9.3 Product Type Portfolio Analysis 12.9.4 Business Strategy & Recent Development 12.10 Acon Laboratories. 12.10.1 Company overview 12.10.2 Financial performance 12.10.3 Product Type Portfolio Analysis 12.10.4 Business Strategy & Recent Development 12.11 Nova BiomedicalLifescan. 12.11.1 Company overview 12.11.2 Financial performance 12.11.3 Product Type Portfolio Analysis 12.11.4 Business Strategy & Recent Development 12.12 Ascensia Diabetes Care. 12.12.1 Company overview 12.12.2 Financial performance 12.12.3 Product Type Portfolio Analysis 12.12.4 Business Strategy & Recent Development 12.13 Dexcom. 12.13.1 Company overview 12.13.2 Financial performance 12.13.3 Product Type Portfolio Analysis 12.13.4 Business Strategy & Recent Development